These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24446829)

  • 1. A physiologically based modeling strategy during preclinical CNS drug development.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Mol Pharm; 2014 Mar; 11(3):836-48. PubMed ID: 24446829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses.
    Kielbasa W; Stratford RE
    Drug Metab Dispos; 2012 May; 40(5):877-83. PubMed ID: 22287668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats.
    Kielbasa W; Kalvass JC; Stratford R
    Drug Metab Dispos; 2009 Jan; 37(1):137-42. PubMed ID: 18936112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.
    Yamamoto Y; Välitalo PA; Wong YC; Huntjens DR; Proost JH; Vermeulen A; Krauwinkel W; Beukers MW; Kokki H; Kokki M; Danhof M; van Hasselt JGC; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 112():168-179. PubMed ID: 29133240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.
    de Lange EC; Hammarlund-Udenaes M
    Clin Pharmacol Ther; 2015 Apr; 97(4):380-94. PubMed ID: 25670219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    AAPS J; 2013 Oct; 15(4):913-32. PubMed ID: 23784110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of CSF in translational neuroscience.
    de Lange EC
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):315-26. PubMed ID: 23400635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.
    Yamamoto Y; Danhof M; de Lange ECM
    AAPS J; 2017 Jul; 19(4):891-909. PubMed ID: 28281195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    J Pharm Sci; 2012 Nov; 101(11):4277-92. PubMed ID: 22864977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A method to predict different mechanisms for blood-brain barrier permeability of CNS activity compounds in Chinese herbs using support vector machine.
    Jiang L; Chen J; He Y; Zhang Y; Li G
    J Bioinform Comput Biol; 2016 Feb; 14(1):1650005. PubMed ID: 26632324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
    Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.
    Deo AK; Theil FP; Nicolas JM
    Mol Pharm; 2013 May; 10(5):1581-95. PubMed ID: 23256608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
    Adenot M; Perriere N; Scherrmann JM; Lahana R
    Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data.
    Gaohua L; Neuhoff S; Johnson TN; Rostami-Hodjegan A; Jamei M
    Drug Metab Pharmacokinet; 2016 Jun; 31(3):224-33. PubMed ID: 27236639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.
    Saleh MAA; Loo CF; Elassaiss-Schaap J; De Lange ECM
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):725-741. PubMed ID: 34142308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential receptor-mediated drug targeting to the diseased brain.
    Rip J; Schenk GJ; de Boer AG
    Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.